Skip to main content
. 2017 Jan 30;35(8):885–892. doi: 10.1200/JCO.2016.70.2951

Fig 1.

Fig 1.

Study schema for the phase III randomized trial of 4 weeks of high-dose interferon-α-2b in patients with intermediate-risk melanoma. IFN, interferon group; IV, intravenously; M-F, Monday to Friday; OBS, observation group.